CoChat
Sign Up
Cited by 171Attention Deficit Hyperactivity DisorderSubstance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.

Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders

Wilens, Timothy E., Adler, Lenard A., Weiss, Margaret D., Michelson, David, Ramsey, Janet L., Moore, Rodney J., Renard, Didier, Brady, Kathleen T., Trzepacz, Paula T., Schuh, Leslie M., Ahrbecker, Lisa M., Levine, Louise R.·2008·Drug and Alcohol Dependence
DOI 10.1016/j.drugalcdep.2008.02.009
Open this paper in CoChat — free account

Abstract

Objective Adults with attention-deficit/hyperactivity disorder (ADHD) have higher rates of alcohol and drug use disorders than adults without ADHD. The study aim was to determine if atomoxetine was superior to placebo in improving ADHD and alcohol use in recently abstinent adults with ADHD and comorbid alcohol use disorder.Methods Adults with DSM-IV diagnoses of ADHD and alcohol abuse and/or dependence were abstinent from alcohol at least 4 days (maximum 30 days) before study randomization. Participants received atomoxetine (25-100mg daily) or placebo for 12 weeks. ADHD symptoms were assessed using ADHD Investigator Symptom Rating Scale (AISRS) total score. Time-to-relapse to heavy alcohol use was analyzed using a 2-sided log-rank test based on Kaplan-Meier estimates and cumulative heavy drinking events over time were evaluated post hoc with recurrent-event analysis.Results Subjects received atomoxetine (n=72) or placebo (n=75) and 80 subjects completed the 12-week double-blind period (n=32 and 48, respectively). ADHD symptoms were significantly improved in the atomoxetine cohort compared to placebo (AISRS total score mean [S.D.], atomoxetine: -13.63 [11.35], P<.001; placebo: -8.31 [11.44], P<.001, difference: P=.007; effect size=0.48). No significant differences between treatment groups occurred in time-to-relapse of heavy drinking (P=.93). However, cumulative heavy drinking days were reduced 26% in atomoxetine-treated subjects versus placebo (event ratio=0.74, P=.023). There were no serious adverse events or specific drug-drug reactions related to current alcohol use.Conclusions This 3-month, double-blind, placebo-controlled study of atomoxetine in adults with ADHD and comorbid alcohol use disorder demonstrates clinically significant ADHD improvement, and inconsistent effects on drinking behavior.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.drugalcdep.2008.02.009

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 171

Related

See all

Metadata

Authors
Wilens, T. E., Adler, L. A., Weiss, M. D., Michelson, D., Ramsey, J. L., Moore, R. J., Renard, D., Brady, K. T., Trzepacz, P. T., Schuh, L. M., Ahrbecker, L. M., & Levine, L. R.
Affiliations
  • Massachusetts General Hospital (US)
  • New York University (US)
  • University of British Columbia (CA)
  • Eli Lilly (United States) (US)
  • Medical University of South Carolina (US)
Corresponding author
Wilens, Timothy E.
ORCID
Venue
Drug and Alcohol Dependence
Publisher
Elsevier BV
Published
2008-07
Volume
96
Issue
1-2
Pages
145-154
ISSN
0376-8716 (ISSN-L)
DOI
10.1016/j.drugalcdep.2008.02.009
OpenAlex
W2061126019
Cited by
171
References
69
Citations by year
2026: 5 · 2025: 3 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 12 · 2020: 8 · 2019: 9 · 2018: 8 · 2017: 10 · 2016: 9 · 2015: 13 · 2014: 14 · 2013: 14 · 2012: 12
FWCI
9.81
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Drug and Alcohol Dependence (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company (5U10DA015831-0, K24 DA016264)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
atomoxetine, adult ADHD, alcoholism, comorbidities, alcohol relapse, heavy drinking, ADHD symptoms, pharmacotherapy
MeSH terms
Atomoxetine Hydrochloride, Adult, Alcohol Drinking, Attention Deficit Disorder with Hyperactivity, Double-Blind Method, Female, Humans, Male, Placebos, Propylamines, Psychiatric Status Rating Scales, Comorbidity, Treatment Outcome, Adrenergic Uptake Inhibitors, Alcohol-Related Disorders, Diagnostic and Statistical Manual of Mental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review